MUTANT BURKHOLDERIA CEPSCIA KM196 STRAIN DEFECT IN OpcPL PORINE PRODUCTION FOR STUDYING OF MOLECULAR MECHANISMS OF MULTIPLE RESISTANCE TO ANTIBIOTICS IN PATHOGENIC BURCHOLDERIA Russian patent published in 2012 - IPC C12N1/20 

FIELD: medicine.

SUBSTANCE: what is described is a new Burkholderia cepscia KM 196 strain carrying nitrosoguanidine (NG) induced mutation in the sequence of opcPl gene responsible for expression of porine protein of molecular weight 36 Da. The strain is produced by two mutagenesis cycles of N-methyl-N'-nitro-N-nitrosoguanidine (NG) of the B.cepacia strain 25416 that is followed by the target recovery of mutant clones in the concentrations of pefloxacin (ofloxacin) and ceftazidime decreasing from the maximum permissible concentration for the initial strain. The clones sensitive to kanamycin, tetracycline, chloramphenicol and deficient in production of major proteins of the external membrane are specified among the mutants with varied sensitivity to cephalosporine and fluoroquinolone antibiotics. The strain 25416 is a version with selected markers of perfloxacine, ofloxacine, ceftazidime, kanamycin, tetracycline, chloramphenicol sensitivity (Pfx^SOfx^SCfz^SKan^STet^SChi^S), deficeint in porine protein OpcPl with M_r 36 kDa and deposited in the State Collection 'Microbe' No. 25416 NSP.

EFFECT: strain shows higher sensitivity to various antibiotics and aims at studying of the molecular-genetic bases of multiple drug resistance in Bcepacia and philogenetically related species of Burcholderia.

2 dwg, 2 tbl, 3 ex